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Have We Come Full Circle, or Are We Chasing Our Tails?*Matthew Wright, MRCP, PHDNothing is impossible to a willing heart
The Proverbs and Epigrams of John Heywood
(A.D. 1562) (1)SEE PAGE 2743T he long-term maintenance of sinus rhythm inpatients in persistent atrial ﬁbrillation (AF)remains a demanding task whatever thera-
peutic option is taken, but it is a challenge electro-
physiologists and surgeons have enthusiastically
pursued for several decades. Buoyed by the clinical
success of catheter ablation of accessory pathways
at the turn of the millennium, it appeared only a mat-
ter of time until AF, be it paroxysmal or persistent,
would become a curable arrhythmia. Yet, despite
intensive investigation, that has not yet come to pass.
The critical role of the pulmonary veins (PVs) in
initiating AF is well established (2), and at least for
paroxysmal AF, PV ablation appears to be sufﬁcient to
treat most patients. With single procedure success
rates (deﬁned by no recurrence of documented
arrhythmia) of approximately 70% at 1 year (3) and
long-term outcomes (3 to 5 years) of 80% for PV
isolation (PVI) with multiple procedures (4,5), this
assumption appears correct for paroxysmal AF. For
patients with persistent AF (sustained arrhythmia
lasting >7 days), the clinical results for PVI as a sole
ablation strategy have been relatively disappointing,
if not at 1 year (6), then certainly at 3- and 5-year
follow-up (7,8). This has led to additional strategies
to modify the atrial substrate. Due to the pioneering
nature of this work, most studies driving clinical
practice over the last decade have been single-center*Editorials published in the Journal of the American College of Cardiology
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the trend continues to be more and more ablation. As
the techniques have become established and posi-
tions entrenched, it is only relatively recently that
systematic meta-analysis (9) and multicenter pro-
spective randomized studies have critically examined
these strategies (10).
ABLATION OF COMPLEX
FRACTIONATED ELECTROGRAMS
One such prospective randomized single-center study
by Vogler et al. (11) is presented in this issue of the
Journal. Using a modiﬁed stepwise ablation strategy,
they randomized patients with persistent AF to either
PVI alone or to additional substrate ablation. The re-
sults suggest that additional substrate ablation offers
little if anything to PVI alone, with 12-month, single-
procedure success rates of 75% and 73.8%, respec-
tively. However, before abandoning this substrate
modiﬁcation for patients with persistent AF, careful
interpretation of these data are required.Temporal classiﬁcation of patients with AF is
fraught with difﬁculty. For example, the TRENDS
data demonstrated that intermittent monitoring and
patient factors inﬂuence clinicians to a greater extent
than expected, leading to misdiagnosis of either
paroxysmal or persistent AF (12,13). As such, although
the intended population was patients with persistent
AF, the duration of continuous AF might have
been <1 week if the patient received early cardio-
version. Although inappropriate diagnosis of parox-
ysmal or persistent AF is likely to inﬂuence all studies
of patients with persistent AF, objective measures,
such as left atrial (LA) diameter and area, AF cycle
length, and CHA2DS2-VASc score, suggest that the
population studied was perhaps more favorable
compared with those in historical retrospective
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2754studies (14–16). For instance, in work by the Bordeaux
group, mean LA diameter and AF cycle length were
approximately 47 mm and 150 ms, respectively (15);
in the current study, these were 44 mm and 170 ms,
respectively. Across numerous studies and groups, LA
diameter and AF cycle length have consistently been
independent markers of freedom from AF following
ablation (5,8,17–19).
Although PVI has become standardized, comparing
ablation techniques is difﬁcult, with the devil being in
the details. The move toward a more antral ablation
approach has undoubtedly improved success rates
(20,21), although whether this is due to additional
substrate ablation, ablation of ganglionic plexi (22), or
inadvertent rotor ablation (23) remains controversial.
Even deﬁning the PV antrum is difﬁcult, let alone
standardizing the complex fractionated atrial elec-
trogram (CFAE). The technique used in the study by
Vogler et al. (11) is described as a stepwise ablation
technique. The original description by the Bordeaux
group of stepwise ablation included PVI, which was
followed by (if necessary) biatrial ablation of CFAEs,
and again (if necessary), linear lesions, followed by
cardioversion, with completion of linear lesions if the
bidirectional block had not already been achieved.
Procedural termination of AF was the endpoint. The
technique used by Vogler et al. (11) was more simply
PVI and then randomization to either cardioversion or
CFAE ablation (24). Linear lesions were only used if a
patient transitioned to a macro–re-entrant tachy-
cardia, which occurred in approximately one-third
of all cases. The Bordeaux stepwise procedure is
certainly an exacting procedure, and Vogler et al. are
right to comment that the modiﬁed technique used in
their study may accurately represent “real-world”
practice.
The data appear to support the STAR-AF II (Sub-
strate and Trigger Ablation for Reduction of Atrial
Fibrillation Trial Part II) trial, in which patients were
randomized in a 1:4:4 manner to either PVI alone,
additive CFAE ablation, or additive linear ablation,
with no beneﬁt shown with additional ablation
compared with PVI alone (10). This was similar to an
earlier randomized study in which the addition of
CFAE ablation to PVI had no discernible effect
regarding rhythm outcome (25). Together, these data
suggest that CFAE ablation added to PVI does not
confer an advantage to the patient in terms of AF-free
survival, but it does increase procedural duration and
bystander atrial ablation. This is substantially
different from suggesting that stepwise ablation, as
deﬁned by the Bordeaux group, does not confer an
advantage, especially because patients who had
termination of AF by PVI alone were excluded fromthe analysis in the study by Vogler et al. (11), equaling
approximately 25% of patients before randomization.
These patients were included in the original
description of the technique, in which termination of
AF by PVI alone was only achieved in 14%, again
suggesting a more advanced AF phenotype in the
original stepwise population compared with the cur-
rent study.
That additional CFAE ablation does not confer a
speciﬁc additional beneﬁt should not be surprising;
the underlying mechanisms of CFAEs are incom-
pletely understood (26), and several different phe-
nomena apparently can give rise to fractionated
electrograms (27). Furthermore, the positive and
negative predictive values of different qualities of
CFAEs are little better than a coin toss (28).
FACTORS CRITICAL TO SUCCESS
The impressive overall AF termination rate in
the study by Vogler et al., using PVI alone, high-
lights several important issues. Patient selection is
clearly critical for achieving long-term technical and
clinical success. Unfortunately, the noninvasive
tools we use are fraught with their own limitations.
Conversely, deﬁning patients based on history and
duration of AF appears simple, but in clinical prac-
tice is decidedly less so (13). Still, a noninvasive
inverse potential mapping system, with limited
availability at present, suggests that an important
change occurs in the AF substrate in patients with
persistent AF for 9 to 12 months, which affects the
amount of ablation necessary to obtain a favorable
rhythm outcome (29). Although cardiac magnetic
resonance imaging (CMR) may categorize patients
with a favorable versus a more unfavorable substrate
(30), so far this has not seen widespread adoption.
Various technical reasons may explain why (31),
ranging from technical facets of the CMR process to
the exact histological characteristics of ﬁbrosis being
assessed (32).
Procedural termination of AF is also somewhat
controversial (5,8,15,16,18,19). Most studies suggest
that procedural termination favors an improved long-
term outcome from AF ablation and independently
predicts success, although the magnitude can vary
from a hazard ratio of 1.28 (19) to 3.8 (16) at 5 years.
Procedural termination of an arrhythmia has been
considered the gold standard from the early days of
radiofrequency ablation, when the mechanism of ar-
rhythmias seemed well understood. The problem
with AF is that currently the underlying mechanisms
are incompletely understood; therefore, although
termination may be the gold standard endpoint,
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2755unless this results from a speciﬁc lesion and a speciﬁc
target (33), AF termination cannot be the ideal
endpoint all of the time.
Although it may appear to a casual observer that
the last decade of extensive LA ablation has come full
circle back to PVI alone as an ablation strategy,
encouragement remains for those of us who under-
take ablation in these complex patients. Data, such as
that presented in this issue of the Journal, should
spur us to critically re-examine for whom and how
persistent AF ablation is undertaken. Improved pa-
tient selection, “the willing heart,” with mechanisti-
cally derived ablation strategies tailored to the
individual patient, may result in more acceptable
long-term success rates.In many ways, this was the ethos of the original
stepwise procedure, with each step only undertaken if
AF had not been terminated. However, to become
widespread clinical practice, the same rigorous in-
dependent examination of novel techniques needs
to be undertaken by the wider community of
electrophysiologists, as has been done with CFAE
ablation in the current study by Vogler et al. (11).
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